Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. louisa-3d

LOUISA-3D

Clinical validation of Laser Optoacoustic Ultrasonic 3D Imaging System Assembly for breast cancer detection and characterization through endogenous biomarkers.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 LOUISA-3D project word cloud

Explore the words cloud of the LOUISA-3D project. It provides you a very rough idea of what is the project "LOUISA-3D" about.

risk    population    deaths    complete    screening    manufactured    view    women    ultrasound    assembly    committee    diagnostic    introducing    bcs    predictive    digital    marked    endogenous    imaging    contrast    trials    capability    ce    evaluation    validating    medical    enter    3d    business    treatment    characterization    blood    saturation    oxygen    trial    functional    release    images    standard    international    modality    content    ultrasonic    bc    market    once    anatomical    media    ionizing    limitations    resolution    scientific    overcome    commercializes    device    bios    full    coregistered    detection    worldwide    sensitivity    opportunity    board    affordable    company    financial    safe    effect    laser    validate    resonance    recall    magnetic    positive    commercialized    cancer    protocols    mammography    tomography    therapy    female    validated    first    plan    enhanced    biomarkers    exogenous    feasibility    radiation    clinical    measuring    combines    neoadjuvant    nat    optoacoustic    louisa    breast    hemoglobin    rate    representing    commercialization    locally   

Project "LOUISA-3D" data sheet

The following table provides information about the project.

Coordinator		 BIOS S.R.L. 

Organization address
address: VIA GUIDO ROSSA, 10/12
city: VIMODROME
postcode: 20090
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Italy [IT]
 Project website https://ec.europa.eu/easme/en/sme/5478/clinical-validation-laser-optoacoustic-ultrasonic-3d-imaging-system-assembly-breast-cancer
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-05-01   to  2015-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BIOS S.R.L. IT (VIMODROME) coordinator 50˙000.00

Map

 Project objective

Breast cancer (BC) is the most common cancer and the first cause of cancer-related deaths in European women. Laser Optoacoustic Ultrasonic 3D Imaging System Assembly (LOUISA-3D) combines optoacoustic functional information from endogenous biomarkers (hemoglobin content and blood oxygen saturation) with high-resolution anatomical images of ultrasound tomography, without the need for ionizing radiation or exogenous contrast media. The objective of LOUISA-3D is to overcome the main limitations of current imaging methods, by validating and introducing to the EU market a novel multi-modality diagnostic device for BC, based on coregistered full view 3D optoacoustic and ultrasonic technology. LOUISA-3D will be a highly effective, safe and affordable imaging method for BC detection, characterization, and evaluation of the effect of neoadjuvant therapy (NAT). Two clinical trials will validate LOUISA-3D. Trial 1 will measure detection rate, recall rate, sensitivity, and positive predictive value of LOUISA-3D as a screening test in a selected female population at increased risk for BC, as compared to standard digital mammography. Trial 2 will assess the LOUISA-3D endogenous biomarkers capability of measuring the NAT effect in the treatment of locally advanced BCs, as compared to contrast-enhanced magnetic resonance imaging. During this feasibility study, an international scientific committee will deliver both trial protocols, and a management board will release a work and financial plan for the trials and a business plan for the production and commercialization of LOUISA-3D, complete market analysis, cost analysis and financial plan. The applying company, Bios, commercializes medical laser systems worldwide. Once validated and CE medical marked, LOUISA-3D will be manufactured and commercialized in EU, representing an important opportunity for Bios to enter the medical imaging market and enable its significant growth.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LOUISA-3D" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LOUISA-3D" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More